Accelerating drug development for amyotrophic lateral sclerosis: construction and application of a disease course model using historical placebo group data

Ruifen Cai,Juan Yang,Lijuan Wu,Yixiao Liu,Xinrui Wang,Qingshan Zheng,Lujin Li
DOI: https://doi.org/10.1186/s13023-024-03057-5
2024-02-04
Orphanet Journal of Rare Diseases
Abstract:Amyotrophic lateral sclerosis (ALS) is an irreversible degenerative disease. Placebo-controlled randomized trials are currently the main trial design to assess the clinical efficacy of drugs for ALS treatment. The aim of this study was to establish models to quantitatively describe the course of ALS, explore influencing factors, and provide the necessary information for ALS drug development.
genetics & heredity,medicine, research & experimental
What problem does this paper attempt to address?